Transform an industry

We invite you to join the CBI Consortium in an important endeavor to shape the future of the biomedical industry. Transforming an industry requires a systematic approach that considers the technical, business, and leadership issues critical to all stakeholders, from early discovery to distribution of products in the marketplace. To foster this transformation, CBI will form strategic partnerships among corporations, government agencies, and academia. These partnerships will design and conduct research projects, develop new curricula, and create new implementation processes to enhance the delivery of innovative therapeutics and devices.

**CBI is a bold new enterprise** that undertakes an ambitious integration and application of science and management. As a university-based research center, CBI functions as a “safe haven” environment within which to discuss and pursue concepts and collaborative work in pre-competitive areas. All stakeholders work together to sustain this distinctive environment, which facilitates CBI’s transformative impact.

**CBI is a “Think and Do” catalyst**, fostering collaboration across a broad range of organizations with diverse imperatives. CBI’s mandate to improve the process of biomedical innovation, the distribution of products and services, and ultimately health care delivery in the U.S., calls for solutions that no constituency can provide alone. Instead, we offer the opportunity for stakeholders to align their efforts.

**MIT is its natural home** where the principles of rigor and relevance to significant world problems continue to guide teaching and research. MIT has a long history of developing interdisciplinary laboratories that contribute to society, as noted by MIT’s President Susan Hockfield:

> With our expertise in interdisciplinary problem solving, MIT is uniquely equipped, and obliged, to make a critical difference: to do the analysis, to create the innovations, to fuel the economy, and to educate the leaders the world needs now.

CBI is well positioned within MIT for this collaboration that harnesses the strength of the academic community, world class teaching hospitals, and the biotechnology, pharmaceutical, device, and diagnostic industries.

**The Leadership Team at MIT**

Other faculty co-directors include Professors Ernst Berndt, Ph.D., from the Sloan School of Management; Steven Tannenbaum, Ph.D., from Biological Engineering and Chemistry, and Anthony Sinskey, Sc.D., from Biology and the Harvard-MIT Division of Health Sciences and Technology (HST). Their representation of three Schools at MIT, as well as HST, exemplifies the collaborative, interdisciplinary nature of the Center.

At MIT, the Center reports directly to MIT’s Vice President for Research and Associate Provost Alice Gast, who also serves as the Chair of the CBI Strategy and Policy Council. The Council’s membership includes 20 world leaders from industry, government, financial institutions, and academia, who advise the Center on strategy, as well as programmatic and financial issues.

**Contact**

For further information about the benefits offered by membership in the CBI Consortium, or about the Center itself, please contact:

**Dr. Frank L. Douglas**, Executive Director

**Center for Biomedical Innovation**

**Massachusetts Institute of Technology**

NE20-382

Three Cambridge Center

Cambridge, MA 02142

Telephone 617.253.0183

Fax 617.253.0687

Email fidoug@mit.edu

http://web.mit.edu/cbi

**Our Mission**

To transform discovery, development, manufacture, and distribution of cost-effective therapeutics and devices through the implementation and dissemination of collaborative research performed by a network of academic, government, and industry experts.
Innovate

Transformational Research Projects
Early last year, in an initial “stakeholder summit,” CBI drew together more than 125 representatives from industry, government, and the academic community, including faculty and staff from MIT and Harvard. Participation from these stakeholders enabled CBI to develop a bold biomedical research agenda of mutual interest and immediate relevance. Summit discussions identified four “action areas” in which change must occur:

- **Safety assessment**
  Improve predictability in preclinical and clinical assessment and post-marketing surveillance through better use of informatics tools and data.

- **Research and development redesign**
  Enhance productivity through new collaboration and research models.

- **Manufacturing and distribution systems**
  Rationalize the supply chain and implement quality-by-design.

- **Risk management — economic and regulatory**
  Apply systematic approaches that anticipate evolution in stratified medicine, regulatory change and reimbursement.

These areas represent leverage points on which researchers can focus their expertise and energy. For the specific transformational research projects identified within these areas, see web.mit.edu/cbi.

Breakthroughs in any of these four areas would have an immediate and significant impact on healthcare innovation and productivity. Clearly, these projects must also address the interests of distinct constituencies: for the academic community, it is to create new ideas and new leaders; for industry, to use resources more effectively in developing new therapies and devices; for regulators, to assure public safety and trust; and for providers and patients, to enhance and benefit from evidence-based medical best practice.

Translate

Transformational Educational Programs
Another vehicle for change is education, including curriculum development for undergraduate and graduate courses and executive education programs focused on strategies for leading biomedical innovation. This portfolio of educational initiatives is designed to address the need for scientific, technical, and managerial expertise required for innovating in the industry.

CBI’s Biopharm Academy
The centerpiece of the transformational educational programs is an academy for training scientists as leaders in the innovation process. At four one-week sessions held over the course of the academic year at MIT, faculty from academia, industry, and government will present tools, frameworks, and systems to address issues such as the following:

- Creating the product pipeline
- Translating discovery into clinical realities
- Delivering products to patients
- Managing product life cycles in a global community
- Evaluating safety pre- and post-approval

Modeled on the uniquely successful British Petroleum Projects Academy, jointly conducted for the past several years at MIT by the School of Engineering and the Sloan School of Management, the Biopharm Academy also incorporates opportunities to address unique challenges faced by individual companies. CBI will launch the Biopharm Academy in fall 2006 and plans to invite stakeholders to assist in refining the curriculum early in 2006.

New curriculum
Industry and government scientists participate with MIT and Harvard faculty in teaching “Case Studies in Drug Discovery and Development,” offered to graduate students at MIT and in the Harvard/MIT Division of Health Sciences and Technology in the spring of 2006.

Collaborate

Consortium Membership
To implement these bold new ideas, CBI must bring together a network of experts to apply science. Sponsor partners provide funding for collaboration on research projects that will energize the innovation and delivery of biomedical products. CBI will engage corporations through a consortium membership model which is commonly used at MIT.

Core Membership
Core membership is offered at $200K per year, for a three year term. This includes participation in three of the transformational research projects (TRPs); a seat on CBI’s Strategy and Policy Council, which sets the Center’s research agenda, vision, and strategy; one complimentary enrollment each year in the Biopharm Academy, and access to a broad array of additional benefits. Early adopters will be recognized as Founding members.

Participating Membership
Participating membership is set at a $50K level per year, for a three year term. This includes full participation in one of the research projects (TRPs) and access to a broad array of additional benefits.

In addition to inviting corporate sponsorship, CBI will seek funding from government agencies and foundations to support specific projects in areas of initial focus, such as oncology and inflammatory disease.

<table>
<thead>
<tr>
<th>Benefits for Consortium Members</th>
<th>Participating Membership</th>
<th>Core Membership</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Year Commitment: Fees per year</td>
<td>$50K</td>
<td>$200K</td>
</tr>
<tr>
<td>Transformational Research Project participation</td>
<td>Number of TRPs</td>
<td>1</td>
</tr>
<tr>
<td>Seat on Strategy and Policy Council</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Biopharm Academy, one enrollment</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Research discussions with MIT faculty and staff, one-on-one</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Access to network of members with specialized expertise in all aspects of drug discovery</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Research briefings, semi-annual or annual</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>CBI conferences, semi-annual</td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>